FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 380 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Little Girl Declared Cancer-Free For The Holidays Following 2 Years Of... December 24, 2021 Jiffy Lube Surprises Volunteer Who Drives Cancer Patients To Treatment With... December 11, 2019 A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... February 5, 2025 FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 Load more HOT NEWS Surveillance and Early Cancer Detection are Associated with Improved Survival in... RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... EMA Recommends Extension of Therapeutic Indications for Nivolumab “Scars are Tattoos with Better Stories”
